Pathol Res Pract:研究发现新型癌基因TRIM63或是治疗乳腺癌的靶点

2019-08-12 sunshine 译 MedSci原创

乳腺癌的发生机制尚未完全明了,目前尚未就乳腺癌的发生和肿瘤转移的过程达成共识。本研究旨在揭示TRIM63与乳腺癌发展之间的相关性。在本研究中,我们发现TRIM63的表达在乳腺癌组织中显著增加,并且与乳腺癌的病理分化和TNM分期密切相关。TRIM63的过表达可明显促进乳腺癌细胞的增殖和迁移,而TRIM63敲低显著抑制乳腺癌细胞的增殖和迁移。此外,TRIM63可激活乳腺癌细胞中的Wnt/β-caten

乳腺癌的发生机制尚未完全明了,目前尚未就乳腺癌的发生和肿瘤转移的过程达成共识。本研究旨在揭示TRIM63与乳腺癌发展之间的相关性。

在本研究中,我们发现TRIM63的表达在乳腺癌组织中显著增加,并且与乳腺癌的病理分化和TNM分期密切相关。TRIM63的过表达可明显促进乳腺癌细胞的增殖和迁移,而TRIM63敲低显著抑制乳腺癌细胞的增殖和迁移。此外,TRIM63可激活乳腺癌细胞中的Wnt/β-catenin信号通路。进一步研究发现TRIM63可通过促进GSK3β磷酸化来调节β-连环蛋白降解。

总之,该研究结果表明,TRIM63作为一种致癌基因,通过激活Wnt/β-catenin信号通路参与乳腺癌的进展,提示TRIM63作为乳腺癌治疗靶点的潜在适用性。

原始出处:

Li K, Pan W, et al., A novel oncogene TRIM63 promotes cell proliferation and migration via activating Wnt/β-catenin signaling pathway in breast cancer. Pathol Res Pract. 2019 Jul 31:152573. doi: 10.1016/j.prp.2019.152573.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786290, encodeId=43b41e86290fe, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 11 19:48:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753489, encodeId=52771e53489ec, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Oct 17 12:48:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373950, encodeId=d8c713e3950a2, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Aug 14 11:48:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
    2020-04-11 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786290, encodeId=43b41e86290fe, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 11 19:48:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753489, encodeId=52771e53489ec, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Oct 17 12:48:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373950, encodeId=d8c713e3950a2, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Aug 14 11:48:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786290, encodeId=43b41e86290fe, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Apr 11 19:48:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753489, encodeId=52771e53489ec, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Oct 17 12:48:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373950, encodeId=d8c713e3950a2, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Wed Aug 14 11:48:00 CST 2019, time=2019-08-14, status=1, ipAttribution=)]